Patient Adherence: A Hard Pill to Swallow?

The Digi-Tech Pharma & AI 2022 conference brings with it even more interactive sessions, expert speakers, senior professionals and decision makers from leading pharma, bio-tech and healthcare industry.

Various neurodegenerative processes result in the development of diseases like Alzheimer’s (AD), Parkinson’s (PD), amyotrophic lateral sclerosis (ALS), and, arguably, multiple sclerosis (MS). Despite years of research, drug discovery initiatives, and promising clinical trials, these diseases remain incurable. But recent studies have suggested common mechanisms underlying these pathologies. Atypical protein assembly resulting in plaque formation is a common pathological finding in both AD and PD, while neuronal death is a primary (ALS) or secondary (MS) hallmark of the disease. For a detailed look at the mechanisms that drive an array of neurodegenerative diseases, The Scientist is bringing together a panel of experts to share their research, discuss current therapeutic approaches, and offer their insights. Come engage with our panel and get the answers you seek.

Antibody Drug Conjugates (ADCs) have a highly specific mechanism of action which is an advantage for the treatment of several oncology indications. They are made of a highly toxic payload, a linker, and an antibody.

It Is Approaching Two Years since Publication of the 2ND Edition Commissioning & Qualification (C&Q) Ispe Baseline Guide.